Erasca stock hits 52-week high at $13.30
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Erasca Inc (ERAS)
Assess today's live Erasca Inc (ERAS) share price, performance and insights using our live NASDAQ: ERAS stock exchange data.
Analyse the historical data and Erasca Inc share price performance charts on this page. Our technical summary section provides analysis on Erasca share price buy/sell indicators using real-time data (or discuss the Erasca (ERAS) stock price today with other investors in the Erasca NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ERAS share price (ISIN: US29479A1088) to enhance your trading decisions with our free investment tools and resources.
What Is the Erasca Inc Share Price Today?
The Erasca share price today is 13.660.
What Is the Stock Symbol for Erasca Inc
The stock symbol (or 'ticker') for Erasca Inc is "ERAS."
What Stock Exchange Does Erasca Inc Trade On?
Erasca Inc is listed and trades on the NASDAQ stock exchange.
Is Erasca Inc a Good Stock to Buy?
Determining whether Erasca Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Erasca Inc share price performance charts on this page. Our technical summary section provides analysis on Erasca share price buy/sell indicators using real-time data (or discuss the Erasca (ERAS) stock price today with other investors in the Erasca NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ERAS share price (ISIN: US29479A1088) to enhance your trading decisions with our free investment tools and resources.
What Is the Erasca Inc Share Price Today?
The Erasca share price today is 13.660.
What Is the Stock Symbol for Erasca Inc
The stock symbol (or 'ticker') for Erasca Inc is "ERAS."
What Stock Exchange Does Erasca Inc Trade On?
Erasca Inc is listed and trades on the NASDAQ stock exchange.
Is Erasca Inc a Good Stock to Buy?
Determining whether Erasca Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.210
13.790
52 wk Range
1.010
14.170
ERAS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.21013.790
52 wk Range
1.01014.170
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ERAS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
11.556
Downside
-15.41%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
- Erasca stock reaches 52-week high at 12.48 USD
- Investing.com
- Erasca stock hits 52-week high at $13.30
- Investing.com
- Erasca stock reaches 52-week high at 12.48 USD
- Investing.com
- Erasca stock hits 52-week high at $10.71
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Erasca Company Profile
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company’s products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Compare ERAS to Peers and Sector
Metrics to compare | ERAS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipERASPeersSector | |
|---|---|---|---|---|
P/E Ratio | −33.1x | −3.8x | −0.6x | |
PEG Ratio | −0.77 | −0.10 | 0.00 | |
Price/Book | 12.2x | 3.2x | 2.6x | |
Price / LTM Sales | - | 63.9x | 3.3x | |
Upside (Analyst Target) | −19.5% | 64.8% | 44.9% | |
Fair Value Upside | Unlock | −5.8% | 5.6% | Unlock |
Analyst Ratings
8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 11.556
(-15.41% Downside)
Earnings
Latest Release
Nov 12, 2025
EPS / Forecast
-0.11 / -0.104
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Erasca (ERAS) Share Price Today?
The Erasca stock price today is 13.660 USD.
What Stock Exchange Does Erasca (ERAS) Trade On?
Erasca is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Erasca?
The stock symbol (also called a 'ticker') for Erasca is "ERAS."
What Is the Current Erasca Market Cap?
As of today, Erasca market cap is 4.230B USD.
What Is Erasca's (ERAS) Earnings Per Share (TTM)?
The Erasca EPS is currently -0.451 (Trailing Twelve Months).
When Is the Next Erasca Earnings Date?
Erasca's next earnings report will be released on 19/03/2026.
Is ERAS a Buy or Sell From a Technical Analyst Perspective?
Based on today's Erasca moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Erasca Stock Split?
Erasca has split 0 times. (See the ERAS stock split history page for full effective split date and price information.)
How Many Employees Does Erasca Have?
Erasca has 103 employees.
What is the current trading status of Erasca (ERAS)?
As of 01/03/2026, Erasca (ERAS) is trading at a price of 13.660 USD, with a previous close of 13.570 USD. The stock has fluctuated within a day range of 13.210 USD to 13.790 USD, while its 52-week range spans from 1.010 USD to 14.170 USD.
What Is Erasca (ERAS) Price Target According to Analysts?
The average 12-month price target for Erasca is 11.556 USD, with a high estimate of 17 USD and a low estimate of 2 USD. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -15.41% Downside potential.
What Is the ERAS Premarket Price?
ERAS's last pre-market stock price is 13.420 USD. The pre-market share volume is 2,010.000, and the stock has decreased by -0.150, or -1.110%.
What Is the ERAS After Hours Price?
ERAS's last after hours stock price is 13.670 USD, the stock has decreased by 0.010, or 0.070%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.